{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:40:43Z","timestamp":1790707243214,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,2,5]],"date-time":"2011-02-05T00:00:00Z","timestamp":1296864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1007\/s10549-011-1364-y","type":"journal-article","created":{"date-parts":[[2011,2,4]],"date-time":"2011-02-04T08:50:00Z","timestamp":1296809400000},"page":"437-447","source":"Crossref","is-referenced-by-count":92,"title":["Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy"],"prefix":"10.1007","volume":"130","author":[{"given":"Scott","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth T.","family":"Thurn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elona","family":"Bi\u00e7aku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas C.","family":"Marchion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela N.","family":"M\u00fcnster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,5]]},"reference":[{"issue":"2","key":"1364_CR1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.canlet.2008.12.026","volume":"280","author":"S Thomas","year":"2009","unstructured":"Thomas S, Munster PN (2009) Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett 280(2):184\u2013191","journal-title":"Cancer Lett"},{"issue":"6","key":"1364_CR2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.bcp.2004.04.031","volume":"68","author":"R Margueron","year":"2004","unstructured":"Margueron R, Duong V, Castet A, Cavailles V (2004) Histone deacetylase inhibition and estrogen signalling in human breast cancer cells. Biochem Pharmacol 68(6):1239\u20131246","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"1364_CR3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/sj.cdd.4401567","volume":"12","author":"BH Huang","year":"2005","unstructured":"Huang BH, Laban M, Leung CH et al (2005) Inhibition of histone deacetylase 2 increases apoptosis and p21cip1\/waf1 expression, independent of histone deacetylase 1. Cell Death Differ 12(4):395\u2013404","journal-title":"Cell Death Differ"},{"issue":"9","key":"1364_CR4","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1535-7163.MCT-05-0480","volume":"5","author":"A Hrzenjak","year":"2006","unstructured":"Hrzenjak A, Moinfar F, Kremser ML et al (2006) Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 5(9):2203\u20132210","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"1364_CR5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1600-0463.2005.apm_04.x","volume":"113","author":"J Song","year":"2005","unstructured":"Song J, Noh JH, Lee JH et al (2005) Increased expression of histone deacetylase 2 is found in human gastric cancer. Apmis 113(4):264\u2013268","journal-title":"Apmis"},{"issue":"5","key":"1364_CR6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1535-6108(04)00114-X","volume":"5","author":"P Zhu","year":"2004","unstructured":"Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M (2004) Induction of hdac2 expression upon loss of apc in colorectal tumorigenesis. Cancer Cell 5(5):455\u2013463","journal-title":"Cancer Cell"},{"issue":"2","key":"1364_CR7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/pros.20022","volume":"59","author":"K Halkidou","year":"2004","unstructured":"Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN (2004) Upregulation and nuclear recruitment of hdac1 in hormone refractory prostate cancer. Prostate 59(2):177\u2013189","journal-title":"Prostate"},{"issue":"2","key":"1364_CR8","first-page":"333","volume":"10","author":"Y Toh","year":"2003","unstructured":"Toh Y, Yamamoto M, Endo K et al (2003) Histone h4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol Rep 10(2):333\u2013338","journal-title":"Oncol Rep"},{"issue":"1","key":"1364_CR9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ijc.20395","volume":"112","author":"H Osada","year":"2004","unstructured":"Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T (2004) Reduced expression of class ii histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 112(1):26\u201332","journal-title":"Int J Cancer"},{"issue":"1","key":"1364_CR10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10549-005-6001-1","volume":"94","author":"Z Zhang","year":"2005","unstructured":"Zhang Z, Yamashita H, Toyama T et al (2005) Quantitation of hdac1 mrna expression in invasive carcinoma of the breast. Breast Cancer Res Treat 94(1):11\u201316","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1364_CR11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-004-1668-2","volume":"90","author":"CA Krusche","year":"2005","unstructured":"Krusche CA, Wulfing P, Kersting C et al (2005) Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat 90(1):15\u201323","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1364_CR12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","volume":"109","author":"M Duvic","year":"2007","unstructured":"Duvic M, Talpur R, Ni X et al (2007) Phase ii trial of oral vorinostat (suberoylanilide hydroxamic acid, saha) for refractory cutaneous t-cell lymphoma (ctcl). Blood 109(1):31\u201339","journal-title":"Blood"},{"issue":"21","key":"1364_CR13","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","volume":"25","author":"EA Olsen","year":"2007","unstructured":"Olsen EA, Kim YH, Kuzel TM et al (2007) Phase iib multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous t-cell lymphoma. J Clin Oncol 25(21):3109\u20133115","journal-title":"J Clin Oncol"},{"issue":"32","key":"1364_CR14","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","volume":"27","author":"RL Piekarz","year":"2009","unstructured":"Piekarz RL, Frye R, Turner M et al (2009) Phase ii multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous t-cell lymphoma. J Clin Oncol 27(32):5410\u20135417","journal-title":"J Clin Oncol"},{"issue":"7","key":"1364_CR15","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1210\/me.2004-0011","volume":"19","author":"D Sharma","year":"2005","unstructured":"Sharma D, Blum J, Yang X, Beaulieu N, Macleod AR, Davidson NE (2005) Release of methyl cpg binding proteins and histone deacetylase 1 from the estrogen receptor alpha (er) promoter upon reactivation in er-negative human breast cancer cells. Mol Endocrinol 19(7):1740\u20131751","journal-title":"Mol Endocrinol"},{"issue":"19","key":"1364_CR16","first-page":"7025","volume":"61","author":"X Yang","year":"2001","unstructured":"Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE (2001) Synergistic activation of functional estrogen receptor (er)-alpha by DNA methyltransferase and histone deacetylase inhibition in human er-alpha-negative breast cancer cells. Cancer Res 61(19):7025\u20137029","journal-title":"Cancer Res"},{"issue":"8","key":"1364_CR17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00432-008-0354-x","volume":"134","author":"J Fan","year":"2008","unstructured":"Fan J, Yin WJ, Lu JS et al (2008) Er alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both hdac inhibitor and dnmt inhibitor. J Cancer Res Clin Oncol 134(8):883\u2013890","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"1364_CR18","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1158\/0008-5472.CAN-07-2822","volume":"68","author":"E Bicaku","year":"2008","unstructured":"Bicaku E, Marchion DC, Schmitt M, Munster PN (2008) Selective inhibition of histone deacetylase 2 silences progesterone receptor mediated signaling. Cancer Res 68(5):1513\u20131519","journal-title":"Cancer Res"},{"issue":"8","key":"1364_CR19","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/carcin\/17.8.1595","volume":"17","author":"W Bursch","year":"1996","unstructured":"Bursch W, Ellinger A, Kienzl H et al (1996) Active cell death induced by the anti-estrogens tamoxifen and ici 164 384 in human mammary carcinoma cells (mcf-7) in culture: The role of autophagy. Carcinogenesis 17(8):1595\u20131607","journal-title":"Carcinogenesis"},{"issue":"3","key":"1364_CR20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000048766","volume":"69","author":"A Bilir","year":"2001","unstructured":"Bilir A, Altinoz MA, Erkan M, Ozmen V, Aydiner A (2001) Autophagy and nuclear changes in fm3a breast tumor cells after epirubicin, medroxyprogesterone and tamoxifen treatment in vitro. Pathobiology 69(3):120\u2013126","journal-title":"Pathobiology"},{"issue":"16","key":"1364_CR21","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1038\/sj.onc.1207521","volume":"23","author":"D Gozuacik","year":"2004","unstructured":"Gozuacik D, Kimchi A (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23(16):2891\u20132906","journal-title":"Oncogene"},{"issue":"3","key":"1364_CR22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-007-9873-4","volume":"112","author":"MA Qadir","year":"2008","unstructured":"Qadir MA, Kwok B, Dragowska WH et al (2008) Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast Cancer Res Treat 112(3):389\u2013403","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"1364_CR23","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1535-7163.MCT-08-0447","volume":"7","author":"JS Samaddar","year":"2008","unstructured":"Samaddar JS, Gaddy VT, Duplantier J et al (2008) A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol Cancer Ther 7(9):2977\u20132987","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"1364_CR24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3816\/CBC.2002.n.002","volume":"2","author":"C Gajdos","year":"2002","unstructured":"Gajdos C, Jordan VC (2002) Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade. Clin Breast Cancer 2(4):272\u2013281","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"1364_CR25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10549-006-9459-6","volume":"105","author":"L Hodges-Gallagher","year":"2006","unstructured":"Hodges-Gallagher L, Valentine CD, Bader SE, Kushner PJ (2006) Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res Treat 105(3):297\u2013309","journal-title":"Breast Cancer Res Treat"},{"issue":"18","key":"1364_CR26","doi-asserted-by":"crossref","first-page":"18384","DOI":"10.1074\/jbc.M313561200","volume":"279","author":"F Scarlatti","year":"2004","unstructured":"Scarlatti F, Bauvy C, Ventruti A et al (2004) Ceramide-mediated macroautophagy involves inhibition of protein kinase b and up-regulation of beclin 1. J Biol Chem 279(18):18384\u201318391","journal-title":"J Biol Chem"},{"issue":"5","key":"1364_CR27","doi-asserted-by":"crossref","first-page":"600","DOI":"10.4161\/auto.6260","volume":"4","author":"B Levine","year":"2008","unstructured":"Levine B, Sinha S, Kroemer G (2008) Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy 4(5):600\u2013606","journal-title":"Autophagy"},{"issue":"12","key":"1364_CR28","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/ncb1206-1317","volume":"8","author":"HL Galonek","year":"2006","unstructured":"Galonek HL, Hardwick JM (2006) Upgrading the bcl-2 network. Nat Cell Biol 8(12):1317\u20131319","journal-title":"Nat Cell Biol"},{"issue":"1","key":"1364_CR29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1152\/physrev.00013.2006","volume":"87","author":"G Kroemer","year":"2007","unstructured":"Kroemer G, Galluzzi L, Brenner C (2007) Mitochondrial membrane permeabilization in cell death. Physiol Rev 87(1):99\u2013163","journal-title":"Physiol Rev"},{"issue":"5698","key":"1364_CR30","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1126\/science.1099993","volume":"306","author":"T Shintani","year":"2004","unstructured":"Shintani T, Klionsky DJ (2004) Autophagy in health and disease: a double-edged sword. Science 306(5698):990\u2013995","journal-title":"Science"},{"issue":"1","key":"1364_CR31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1006\/geno.1999.5851","volume":"59","author":"VM Aita","year":"1999","unstructured":"Aita VM, Liang XH, Murty VV et al (1999) Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 59(1):59\u201365","journal-title":"Genomics"},{"issue":"12","key":"1364_CR32","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/nrc2254","volume":"7","author":"R Mathew","year":"2007","unstructured":"Mathew R, Karantza-Wadsworth V, White E (2007) Role of autophagy in cancer. Nat Rev Cancer 7(12):961\u2013967","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1364_CR33","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/sj.cdd.4402030","volume":"14","author":"M Katayama","year":"2007","unstructured":"Katayama M, Kawaguchi T, Berger MS, Pieper RO (2007) DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ 14(3):548\u2013558","journal-title":"Cell Death Differ"},{"issue":"2","key":"1364_CR34","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1172\/JCI28833","volume":"117","author":"RK Amaravadi","year":"2007","unstructured":"Amaravadi RK, Yu D, Lum JJ et al (2007) Autophagy inhibition enhances therapy-induced apoptosis in a myc-induced model of lymphoma. J Clin Invest 117(2):326\u2013336","journal-title":"J Clin Invest"},{"issue":"3","key":"1364_CR35","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/sj.cdd.4402039","volume":"14","author":"MJ Abedin","year":"2007","unstructured":"Abedin MJ, Wang D, Mcdonnell MA, Lehmann U, Kelekar A (2007) Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ 14(3):500\u2013510","journal-title":"Cell Death Differ"},{"issue":"3","key":"1364_CR36","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4161\/auto.5.3.7784","volume":"5","author":"PV Schoenlein","year":"2009","unstructured":"Schoenlein PV, Periyasamy-Thandavan S, Samaddar JS, Jackson WH, Barrett JT (2009) Autophagy facilitates the progression of eralpha-positive breast cancer cells to antiestrogen resistance. Autophagy 5(3):400\u2013403","journal-title":"Autophagy"},{"issue":"4","key":"1364_CR37","doi-asserted-by":"crossref","first-page":"e10240","DOI":"10.1371\/journal.pone.0010240","volume":"5","author":"V Espina","year":"2010","unstructured":"Espina V, Mariani BD, Gallagher RI et al (2010) Malignant precursor cells pre-exist in human breast dcis and require autophagy for survival. PLoS One 5(4):e10240","journal-title":"PLoS One"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1364-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-011-1364-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-011-1364-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:33:42Z","timestamp":1559234022000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-011-1364-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,5]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["1364"],"URL":"https:\/\/doi.org\/10.1007\/s10549-011-1364-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,5]]}}}